Imlygic (Amgen Inc)
Welcome to the PulseAid listing for the Imlygic drug offered from Amgen Inc. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Amgen Inc |
| NON-PROPRIETARY NAME: | talimogene laherparepvec |
| SUBSTANCE NAME: | TALIMOGENE LAHERPAREPVEC |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | INTRALESIONAL |
| DOSAGE FORM: | INJECTION, SUSPENSION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2015-11-02 |
| END MARKETING DATE: | 0000-00-00 |
Imlygic HUMAN PRESCRIPTION DRUG Details:
| Item Description | Imlygic from Amgen Inc |
| LABELER NAME: | Amgen Inc |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1000000([PFU]/mL) |
| START MARKETING DATE: | 2015-11-02 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 55513-078_1fc8ef9c-e6a3-4a92-be6a-4718327022bd |
| PRODUCT NDC: | 55513-078 |
| APPLICATION NUMBER: | BLA125518 |
Other TALIMOGENE LAHERPAREPVEC Pharmaceutical Manufacturers / Labelers:
